The announcement of a class action lawsuit against Kyverna Therapeutics is likely to negatively impact its stock price in the short term as it raises concerns about potential financial liabilities and investor sentiment. The deadline for lead plaintiffs is February 7, 2025, which may keep the issue in focus for investors.